BMRN
NASD BioMarin Pharmaceutical Inc.$56.50 ↑ +0.45 (+0.80%) Trading Up from the previous close of $56.05
- YTD change
- -4.93%
- vs 20-day SMA
- -3.40%
- vs 200-day SMA
- -3.56%
Price ranges
Price & Performance
+1.95 (+3.60%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 57.2% away from all-time highs of $131.95
- BMRN is down 5% since the beginning of the year
- BMRN is up 7% over the past 12 months
- BMRN is down 13% over the past 1 month
- 6% of all BMRN investors are betting against BMRN
BMRN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +5.9%.
- Previous minute
- +$0.00
- Last hour
- +$0.10
- Last 5 days
- +2.93%
- vs 8-day SMA
- +2.25%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
